| Firm | Analyst |
|---|---|
|
Barclays
|
Peter Lawson, DPhil (Oxon) |
|
Brookline Capital Markets
|
Leah Cann |
|
Cowen and Company
|
Phil Nadeau, Ph.D. |
|
Credit Suisse
|
Tiago Fauth |
|
H.C. Wainwright & Co.
|
Joseph Pantginis, Ph.D. |
|
JMP Securities
|
Reni Benjamin, Ph.D. |
|
Stifel
|
In transition |
|
SVB Leerink
|
Jonathan Chang, Ph.D., CFA |
|
Wedbush
|
Robert Driscoll, Ph.D. |
Kura Oncology, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Kura Oncology, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kura Oncology, Inc. or its management. Kura Oncology, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.